Ulixacaltamide

The phase 3 evidence supports short-term improvement in daily functioning versus placebo and maintenance of benefit during randomized withdrawal among selected responders. Treatment discontinuations, differential inclusion in the Study 1 mITT analysis, and the responder-enriched Study 2 design limit interpretation. Essential1 did not meet its primary endpoint. Ulixacaltamide remains investigational; the reported FDA target action date is January 29, 2027, rather than an approval date. Comparative effectiveness against established therapies and product-specific economic value remain undetermined in the evidence collected here.